MCLA-129 — Investigational Agent
Bispecific Antibody · Phase 1/2 · Merus / Betta Pharmaceuticals
Mechanism of Action
Humanized bispecific IgG1 antibody simultaneously targeting EGFR and c-MET, blocking ligand-dependent signaling and driving enhanced antibody-dependent cellular cytotoxicity via ADCC-enhancing Fc engineering. Dual targeting counters MET-driven resistance to EGFR inhibition.
Investigational Indications
- EGFR-mutant non-small cell lung cancer
- MET-altered NSCLC
- Advanced solid tumors